Spots Global Cancer Trial Database for seattle genetics

Every month we try and update this database with for seattle genetics cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Safety Study of SGN-35T in Adults With Advanced Cancers	NCT06120504	Lymphoma, T-Cel... Hodgkin Disease Lymphoma, T-Cel... Lymphoma, Large... Lymphoma, Large... Lymphoma, Non-H...	SGN-35T	18 Years -	Seagen Inc.
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL	NCT04404283	Diffuse Large B...	Brentuximab ved... Rituximab Lenalidomide Placebo	18 Years -	Seagen Inc.
A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors	NCT05571839	Cutaneous Melan... Non-small Cell ... Colorectal Neop... Pancreatic Neop... Mesothelioma	SGN-BB228	18 Years -	Seagen Inc.
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors	NCT06131840	Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung...	SGN-CEACAM5C	18 Years -	Seagen Inc.
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors	NCT04609566	Melanoma Non-small Cell ... Squamous Cell C...	brentuximab ved... pembrolizumab	18 Years -	Seagen Inc.
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer	NCT03310957	Triple Negative...	ladiratuzumab v... Pembrolizumab	18 Years -	Seagen Inc.
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)	NCT01716806	Hodgkin Disease Peripheral T Ce...	brentuximab ved... bendamustine dacarbazine nivolumab	18 Years -	Seagen Inc.
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)	NCT03657043	Ovarian Cancer Fallopian Tube ... Peritoneal Canc...	tisotumab vedot...	18 Years -	Seagen Inc.
A Safety Study of SGN-LIV1A in Breast Cancer Patients	NCT01969643	HER2 Positive B... Hormone Recepto... Triple Negative... HER2 Mutations ...	ladiratuzumab v... Trastuzumab	18 Years -	Seagen Inc.
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations	NCT04579380	Uterine Neoplas... Uterine Cervica... Biliary Tract N... Urologic Neopla... Carcinoma, Non-... HER2 Mutations ...	tucatinib trastuzumab fulvestrant	18 Years -	Seagen Inc.
A Study of SGN-B7H4V in Advanced Solid Tumors	NCT05194072	Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... Triple Negative... HER2 Negative B... Hormone Recepto... Endometrial Neo... Carcinoma, Non-... Cholangiocarcin... Gallbladder Car... Adenoid Cystic ...	SGN-B7H4V	18 Years -	Seagen Inc.
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer	NCT06012435	Carcinoma, Non-...	sigvotatug vedo... docetaxel	18 Years -	Seagen Inc.
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors	NCT04032704	Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma	ladiratuzumab v... pembrolizumab	18 Years -	Seagen Inc.
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors	NCT04032704	Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma	ladiratuzumab v... pembrolizumab	18 Years -	Seagen Inc.
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer	NCT04254107	Non-small Cell ... Gastric Carcino... Gastroesophagea... Classical Hodgk... Diffuse Large B... Peripheral T-ce... Cutaneous Melan... Head and Neck S... Bladder Cancer Ovarian Cancer Triple Negative... Cervical Cancer	SEA-TGT sasanlimab brentuximab ved...	18 Years -	Seagen Inc.
A Study of SGN-STNV in Advanced Solid Tumors	NCT04665921	Carcinoma, Non-... HER2 Negative B... Ovarian Neoplas... Uterine Cervica... Endometrial Neo... Esophageal Neop... Gastroesophagea... Stomach Neoplas... Colorectal Neop... Exocrine Pancre... Appendiceal Ade... Pseudomyxoma Pe...	SGN-STNV	18 Years -	Seagen Inc.
A Study of SGN-PDL1V in Advanced Solid Tumors	NCT05208762	Carcinoma, Non-... Squamous Cell C... Esophageal Squa... Ovarian Neoplas... Melanoma Triple Negative... Gastric Cancer	SGN-PDL1V pembrolizumab	18 Years -	Seagen Inc.
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer	NCT03043313	Metastatic Colo...	Trastuzumab Tucatinib	18 Years -	Seagen Inc.
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer	NCT05253651	Colorectal Neop...	tucatinib trastuzumab bevacizumab cetuximab oxaliplatin leucovorin levoleucovorin fluorouracil	18 Years -	Seagen Inc.
A Study of SGN-PDL1V in Advanced Solid Tumors	NCT05208762	Carcinoma, Non-... Squamous Cell C... Esophageal Squa... Ovarian Neoplas... Melanoma Triple Negative... Gastric Cancer	SGN-PDL1V pembrolizumab	18 Years -	Seagen Inc.
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL	NCT04404283	Diffuse Large B...	Brentuximab ved... Rituximab Lenalidomide Placebo	18 Years -	Seagen Inc.
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer	NCT05132582	HER2 Positive B...	Tucatinib Trastuzumab Pertuzumab Combination pro... Placebo	18 Years -	Seagen Inc.
A Study of SGN-CD228A in Advanced Solid Tumors	NCT04042480	Cutaneous Melan... Pleural Mesothe... HER2 Negative B... Non-small Cell ... Colorectal Canc... Pancreatic Duct...	SGN-CD228A	18 Years -	Seagen Inc.
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors	NCT03485209	Colorectal Neop... Carcinoma, Non-... Exocrine Pancre... Carcinoma, Squa...	tisotumab vedot... pembrolizumab carboplatin cisplatin	18 Years -	Seagen Inc.
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer	NCT03043313	Metastatic Colo...	Trastuzumab Tucatinib	18 Years -	Seagen Inc.
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies	NCT04227847	Myelodysplastic... Acute Myeloid L...	SEA-CD70 azacitidine	18 Years -	Seagen Inc.
A Study of SEA-CD40 Given With Other Drugs in Cancers	NCT04993677	Melanoma Carcinoma, Non-...	SEA-CD40 pembrolizumab pemetrexed carboplatin	18 Years -	Seagen Inc.
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)	NCT03657043	Ovarian Cancer Fallopian Tube ... Peritoneal Canc...	tisotumab vedot...	18 Years -	Seagen Inc.
Safety Study of SEA-CD40 in Cancer Patients	NCT02376699	Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden...	Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel	18 Years -	Seagen Inc.
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression	NCT04569032	Peripheral T-ce...	brentuximab ved... cyclophosphamid... doxorubicin prednisone	18 Years -	Seagen Inc.
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers	NCT04430738	Colorectal Carc... Gastric Adenoca... GEJ Adenocarcin... Esophageal Aden... Cholangiocarcin... Gallbladder Car...	tucatinib trastuzumab oxaliplatin leucovorin fluorouracil capecitabine pembrolizumab	18 Years -	Seagen Inc.
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study	NCT05902494	Urothelial Carc...		18 Years -	Seagen Inc.
Safety Study of SEA-CD40 in Cancer Patients	NCT02376699	Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden...	Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel	18 Years -	Seagen Inc.
A Study of SGN-ALPV in Advanced Solid Tumors	NCT05229900	Ovarian Neoplas... Endometrial Neo... Carcinoma, Non-... Stomach Neoplas... Gastroesophagea... Uterine Cervica... Testicular Neop...	SGN-ALPV	18 Years -	Seagen Inc.
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors	NCT04032704	Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma	ladiratuzumab v... pembrolizumab	18 Years -	Seagen Inc.
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer	NCT02614794	HER2 Positive B...	tucatinib capecitabine trastuzumab placebo	18 Years -	Seagen Inc.
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2	NCT04879329	Urothelial Carc...	disitamab vedot... pembrolizumab	18 Years -	Seagen Inc.
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors	NCT06157892	Breast Neoplasm... Gastroesophagea... HER2 Low Breast... HER2 Positive B... Stomach Neoplas... Triple Negative...	disitamab vedot... tucatinib	18 Years -	Seagen Inc.
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer	NCT04539938	HER2 Positive B...	tucatinib trastuzumab der...	18 Years -	Seagen Inc.
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer	NCT06012435	Carcinoma, Non-...	sigvotatug vedo... docetaxel	18 Years -	Seagen Inc.
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer	NCT03975647	HER2-positive B...	tucatinib placebo T-DM1	18 Years -	Seagen Inc.
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer	NCT04697628	Cervical Cancer	tisotumab vedot... topotecan vinorelbine gemcitabine irinotecan pemetrexed	18 Years -	Seagen Inc.
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations	NCT04579380	Uterine Neoplas... Uterine Cervica... Biliary Tract N... Urologic Neopla... Carcinoma, Non-... HER2 Mutations ...	tucatinib trastuzumab fulvestrant	18 Years -	Seagen Inc.
A Study of SGN-CD228A in Advanced Solid Tumors	NCT04042480	Cutaneous Melan... Pleural Mesothe... HER2 Negative B... Non-small Cell ... Colorectal Canc... Pancreatic Duct...	SGN-CD228A	18 Years -	Seagen Inc.
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors	NCT06131840	Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung...	SGN-CEACAM5C	18 Years -	Seagen Inc.
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors	NCT06131840	Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung...	SGN-CEACAM5C	18 Years -	Seagen Inc.
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer	NCT04539938	HER2 Positive B...	tucatinib trastuzumab der...	18 Years -	Seagen Inc.
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors	NCT04032704	Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma	ladiratuzumab v... pembrolizumab	18 Years -	Seagen Inc.
A Safety Study of SGN-LIV1A in Breast Cancer Patients	NCT01969643	HER2 Positive B... Hormone Recepto... Triple Negative... HER2 Mutations ...	ladiratuzumab v... Trastuzumab	18 Years -	Seagen Inc.
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)	NCT01716806	Hodgkin Disease Peripheral T Ce...	brentuximab ved... bendamustine dacarbazine nivolumab	18 Years -	Seagen Inc.
A Study of SGN-B7H4V in Advanced Solid Tumors	NCT05194072	Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... Triple Negative... HER2 Negative B... Hormone Recepto... Endometrial Neo... Carcinoma, Non-... Cholangiocarcin... Gallbladder Car... Adenoid Cystic ...	SGN-B7H4V	18 Years -	Seagen Inc.
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2	NCT04879329	Urothelial Carc...	disitamab vedot... pembrolizumab	18 Years -	Seagen Inc.
A Study of SGN-B6A in Advanced Solid Tumors	NCT04389632	Carcinoma, Non-... Squamous Cell C... HER2 Negative B... Esophageal Squa... Esophageal Aden... Gastroesophagea... Ovarian Neoplas... Cutaneous Squam... Exocrine Pancre... Urinary Bladder... Uterine Cervica... Stomach Neoplas...	sigvotatug vedo... pembrolizumab cisplatin carboplatin	18 Years -	Seagen Inc.
A Safety Study of SGN-35T in Adults With Advanced Cancers	NCT06120504	Lymphoma, T-Cel... Hodgkin Disease Lymphoma, T-Cel... Lymphoma, Large... Lymphoma, Large... Lymphoma, Non-H...	SGN-35T	18 Years -	Seagen Inc.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: